Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Mechanisms Governing Peptide Nanodisc Assembly and Stability.

bioRxiv : the preprint server for biology·2026
Same author

Erratum: Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 <i>in vitro</i> and <i>in vivo</i> in NB xenografts.

Molecular therapy. Oncology·2026
Same author

Peptide nanodiscs: Versatile platforms for membrane protein functional reconstitution and structural studies: A review.

International journal of biological macromolecules·2025
Same author

Bifunctional nanodisc platforms for studies on self-assembly and amyloid fibrillation.

Chemical communications (Cambridge, England)·2025
Same author

Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 <i>in vitro</i> and <i>in vivo</i> in NB xenografts.

Molecular therapy. Oncology·2024
Same author

Characterization of nanodisc-forming peptides for membrane protein studies.

Journal of colloid and interface science·2023

Related Experiment Video

Updated: May 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Apolipoprotein E mimetics and cholesterol-lowering properties.

Oleg F Sharifov1, Gaurav Nayyar, David W Garber

  • 1Departments of Medicine, Biochemistry and Molecular Genetics and the Atherosclerosis Research Unit, University of Alabama at Birmingham, USA.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|December 14, 2011
PubMed
Summary
This summary is machine-generated.

A novel dual-domain peptide, Ac-hE18A-NH(2), mimics apolipoprotein E (apoE) to effectively clear atherogenic lipoproteins. This peptide shows promise for treating dyslipidemias by enhancing hepatic uptake via heparan sulfate proteoglycan (HSPG).

More Related Videos

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Related Experiment Videos

Last Updated: May 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Apolipoprotein E (apoE) plays a crucial role in clearing lipoprotein remnants and possesses anti-atherogenic and anti-inflammatory properties.
  • Existing research focuses on apoE-mimetic peptides for inflammatory conditions like Alzheimer's disease.
  • Peptides that mimic apoE's function in clearing atherogenic lipoproteins via hepatic uptake have not been comprehensively reviewed.

Purpose of the Study:

  • To design and study a novel dual-domain apoE mimetic peptide, Ac-hE18A-NH(2).
  • To investigate the peptide's efficacy in reducing plasma cholesterol levels in dyslipidemic animal models.
  • To explore the mechanism of hepatic uptake via heparan sulfate proteoglycan (HSPG), bypassing the low-density lipoprotein receptor.

Main Methods:

  • Design of a dual-domain peptide (Ac-hE18A-NH(2)) combining the apoE receptor-binding region (residues 141-150) with a class A amphipathic helix (18A).
  • Evaluation of the peptide's effects on plasma cholesterol levels in dyslipidemic mouse and rabbit models.
  • Literature review to support the scientific rationale and efficacy of apoE mimetics.

Main Results:

  • The peptide Ac-hE18A-NH(2) demonstrated significant reduction in plasma cholesterol levels in dyslipidemic mouse and rabbit models.
  • The peptide facilitates hepatic uptake of atherogenic lipoproteins via HSPG, independent of the low-density lipoprotein receptor.
  • The peptide's design rationale and efficacy are supported by scientific literature.

Conclusions:

  • The dual-domain apoE mimetic peptide Ac-hE18A-NH(2) effectively reduces atherogenic lipoproteins.
  • This peptide offers a potential therapeutic strategy for dyslipidemias, including familial hyperlipidemia and atherosclerosis, by utilizing HSPG for hepatic uptake.
  • ApoE mimetics may restore or replace apoE function in conditions with impaired low-density lipoprotein receptor activity.